Case Study: 63-Year-Old Man With Multiple Myeloma

News
Video

A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
Photo of a woman with dark curly hair wearing a floral shirt
Image of a woman with gray hair on a light blue background
Photo of a woman with a blue border around the image
Image of a woman with dark hair wearing a floral shirt in front of a blurred background
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Related Content
Image that reads "FDA Approved" resembling a seal of approval

Linvoseltamab Gains FDA Accelerated Approval In R/R Myeloma

Bridget Hoyt
July 2nd 2025
Article

The FDA has given accelerated approval to the BiTE, linvoseltamab, for use in the fifth line of therapy for relapsed/refractory multiple myeloma.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Graphic of myeloma cells

Q&A: Transitioning Myeloma Care to the Community Level

Bridget Hoyt
June 27th 2025
Article

Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according to Diane Moran, RN, MA, EdM.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Lindsay Fischer
April 13th 2023
Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Illustration of two medical workers holding up a magnifying glass to a cross-section of a bone

Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment

Bridget Hoyt
June 21st 2025
Article

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.

Line illustration of blood cells on a blue background

Teclistamab Safe, Effective for Older Adults With Multiple Myeloma

Roman Fabbricatore
May 26th 2025
Article

CRS and ICANS rates were similar in adults 75 years or older vs younger individuals with relapsed/refractory multiple myeloma.